At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The BASE Study: Bicarbonate Administration to Stabilize eGFR
In Brief
A Phase 3 clinical trial evaluating Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, and 1 other intervention for Chronic Kidney Disease. Completed, enrolled 194 participants across 7 sites.
Detailed Summary
The two doses of sodium bicarbonate being tested are 0.5 and 0.8 mEq/kg-lean body weight (LBW) per day. Sodium bicarbonate, also known as baking soda, may help prevent kidney failure in people with chronic kidney disease. However, the dose to prescribe in order to test this possibility in a clinical trial is uncertain. The BASE pilot clinical trial will help determine the best dose of sodium bicarbonate to prescribe in a future study that will test the long-term safety and efficacy of sodium bicarbonate as a treatment to preserve kidney function in individuals with chronic kidney disease.
Study Details
Timeline
Interventions
Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate